Effects of enhancer of zeste homolog 2 and mucin 1 expressions on treatment response in breast cancer
Open Access
- 1 January 2023
- journal article
- research article
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 69 (1) , 153-158
Abstract
Breast cancer is the most common malignancy in women. In the treatment of these patients, pathological complete response is defined as the absence of invasive cancer in breast or lymph node tissue after the completion of neoadjuvant chemotherapy. In this study, we aimed to investigate the relationship of enhancer of zeste homolog 2 and mucin 1 expressions with pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy. A total of 151 patients were included in the study. Enhancer of zeste homolog 2 and mucin 1 expressions were evaluated in the biopsy materials pre-neoadjuvant chemotherapy and post-neoadjuvant chemotherapy surgical material, and their relationship with pathological complete response was investigated. The pathological complete response rates were significantly higher among the hormone receptor-negative patients, those with a high Ki-67 score, and patients with HER2-positive. Higher pathological complete response rates were obtained from patients with enhancer of zeste homolog 2 expression positivity pre-neoadjuvant chemotherapy. In addition, after neoadjuvant chemotherapy, enhancer of zeste homolog 2 expression was found to be completely negative in materials with pathological complete response; that is, in breast tissues considered to be tumor-free. While there was no significant relationship between mucin 1 expression and pathological complete response pre-neoadjuvant chemotherapy, mucin 1 expression was determined to significantly differ between the tissues with and without pathological complete response among the surgical materials examined. In our study investigating the relationship between enhancer of zeste homolog 2 and mucin 1 expression and pathological complete response in patients who received neoadjuvant chemotherapy, we found that enhancer of zeste homolog 2 expression could be used as a predictive marker for pathological complete response. However, mucin 1 expression was not associated with pathological complete response.Keywords
This publication has 22 references indexed in Scilit:
- Neoadjuvant Therapy in the Treatment of Breast CancerSurgical Oncology Clinics of North America, 2014
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisThe Lancet, 2014
- Ki-67 as a Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer PatientsJournal of Breast Cancer, 2014
- Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancerAnnals of Oncology, 2013
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer SubtypesJournal of Clinical Oncology, 2012
- Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast CancerAnnals of Surgical Oncology, 2011
- Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant ChemotherapyJournal of Clinical Oncology, 2007
- Achieving Higher Pathological Complete Response Rates in HER-2–Positive Patients With Induction Chemotherapy Without Trastuzumab in Operable Breast CancerThe Oncologist, 2007
- Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone ReceptorsClinical Cancer Research, 2004
- Pathobiology of preoperative chemotherapyCancer, 2002